Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six‐Month Prospective Clinical Intervention

• Published in: Journal of bone and mineral research 2017-08, Vol.32 (8), p.1659-1666
• Main Authors: Li, Shan‐Shan, He, Jin‐We, Fu, Wen‐Zhen, Liu, Yu‐Juan, Hu, Yun‐Qiu, Zhang, Zhen‐Lin
• Format: Article
• Language: English
• Subjects: 15-Hydroxyprostaglandin dehydrogenase (NAD+); Adult; Asian Continental Ancestry Group; BONE MODELING AND REMODELING; Bone turnover; China; CLINICAL TRIALS; Cyclooxygenase-2; Dinoprostone - urine; DISEASES AND DISORDERS OF/RELATED TO BONE; Family; Female; GENETIC RESEARCH; Hemorrhage; Humans; Joint diseases; Male; Metabolism; Middle Aged; Mutation; Organic Anion Transporters - genetics; Osteoarthropathy, Primary Hypertrophic - drug therapy; Osteoarthropathy, Primary Hypertrophic - genetics; Osteoarthropathy, Primary Hypertrophic - pathology; Osteoarthropathy, Primary Hypertrophic - urine; Prospective Studies; Prostaglandin E2; Pyridines - administration & dosage; Sex hormones; Sulfones - administration & dosage; THERAPEUTICS
• ISSN: 0884-0431; 1523-4681
• DOI: 10.1002/jbmr.3157

ABSTRACT Primary hypertrophic osteoarthropathy (PHO) is a rare inherited disease caused by genetic defects in the prostaglandin metabolism pathway; disturbed prostaglandin E2 (PGE2) catabolism resulting in increased PGE2 level is suggested in the pathogenesis. Forty‐three Han Chinese patients with PHO were studied and 41 of them were treated. Mutations in the HPGD gene, causing hypertrophic osteoarthropathy, primary, autosomal recessive 1 (PHOAR1; OMIM 259100), were identified in seven patients, and mutations in the SLCO2A1 gene, causing hypertrophic osteoarthropathy, primary, autosomal recessive 2 (PHOAR2; OMIM 614441), were identified in 36 patients. Clinical phenotypes of PHO varied, ranging from mild isolated finger clubbing to severe pachydermia and disabling joint swelling, even within families. Circulating PGE2 metabolism features of PHOAR2 were different from those of PHOAR1. Different frequency and severity of pachydermia between the subgroups were also indicated. A percentage of PHOAR2 patients suffered from gastrointestinal hemorrhage, but this symptom was not observed in the PHOAR1 subgroup. Clinical evidence highlighted the essential role of sex hormones in prostaglandin transporter regulation with respect to PHOAR2 onset, although no significant associations of urinary PGE2 or PGE‐M with sex hormones were identified. Treatment with etoricoxib, a selective cyclooxygenase‐2 inhibitor, was proved to be beneficial and safe. We detected its notable efficacy in decreasing urinary PGE2 levels in the majority of the enrolled patients during 6 months of intervention; clinical phenotypes assessed, including pachydermia, finger clubbing, and joint swelling, were improved. We found no visible evidence of a positive effect of etoricoxib on periostosis; however, significant links between urinary PGE2 and serum bone turnover markers indicated a potential role of decreased PGE2 in periostosis management. This is the largest reported cohort of subjects genetically diagnosed with PHO. For the first time, we systematically investigated the biochemical and clinical differences between PHOAR1 and PHOAR2, and prospectively showed the positive efficacy and safety of etoricoxib for PHO patients. © 2017 American Society for Bone and Mineral Research.